Clinical Trials Browser

Phase 1/2 × Multiple Myeloma × dostarlimab × Clear all

NCT04126200 2026-05-06

DREAMM 5

Phase 1/2 Active not recruiting

208 enrolled 5 charts

Multiple Myeloma

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Multiple Myeloma